Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

February 12, 2018

LakePharma buys Hopkinton facility for $4.5M

Google LakePharma has purchased this Hopkinton building for $4.5 million.

The California bioscience company once considered to be the anchor of a Worcester biomanufacturing campus is planning to open a new facility in a 69,000-square-foot Hopkinton building. 

The property, at 35 South St., will be developed for LakePharmas’ microbiomanufacturing center, where the company will conduct phase 1 clinical trials. 

According to the Middlesex County Registry of Deeds, the company purchased the property from Michigan-based property managers Midway Corp. for just over $4.5 million in December.

The company plans to add about 100 jobs at the site by 2020, LakePharma said in a press release Monday.

When ready, the site will support the company’s assay development, bioanalytical and process development and quality control services. 

The company was once a prospective anchor tenant for a large biomanufacturing campus under development by the Worcester Business Development Corp. at the former Worcester State Hospital site, but pulled out of the project in September.

LakePharma still operates a facility in Worcester at the Worcester Polytechnic Institute campus and plans to double the size of that operation this year. 

The company in December said it raised $30 million to open additional locations in Massachusetts and California, but didn’t disclose the location until Monday.

In a statement, LakePharma CEO Hua Tu said the new facility will allow for fully integrated contract development and manufacturing organization capabilities.

The site is a short drive to Boston and the surrounding area, where a large cluster of biotechs and LakePharma customers exist.

“We will soon be able to provide our clients and partners with the end-to-end services they demand,” Tu said.

According to the Massachusetts Biotechnology Council, the building was previously occupied by Bristol-Myers Squibb and Olympus Biotech before that.

Sign up for Enews

WBJ Web Partners

Related Content

0 Comments

No More articles left

To read more, please
Login or Register (free)

 

To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy

Allow Cookies